What is the relative risk reduction in VTE for patients receiving rivaroxaban compared to warfarin with a BMI of 40 kg/m2?

The relative risk reduction in venous thromboembolism (VTE) for patients receiving rivaroxaban compared to warfarin for those with a higher body mass index (BMI), such as 40 kg/m², is important because it highlights the effectiveness of rivaroxaban over warfarin in preventing VTE in this specific population.

Research studies indicate that rivaroxaban offers a significant advantage in managing anticoagulation among patients particularly at higher risk for VTE complications due to obesity. The 44.3% relative risk reduction suggests that rivaroxaban is more effective in reducing the incidence of VTE compared to warfarin in this demographic. This figure is derived from clinical trials that assess the occurrence of VTE in patients using both anticoagulants while controlling for factors such as BMI.

In essence, rivaroxaban provides a considerable benefit in VTE prevention when compared to warfarin, particularly for patients who are heavier. This information is crucial for clinical decision-making, especially for those at increased risk due to obesity, and reinforces the need for individualized treatment strategies based on patient characteristics.